Suchergebnisse - "Peeters, Monika"

PubPharm (109)

1

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2) : results of a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Infectious diseases | 2022

von Hardt, K. | Vandebosch, A. | Sadoff, J. | +115

CommentIn: Lancet Infect Dis. 2022 Dec;22(12):1654-1655. - PMID 36113536

2

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

enthalten in: The New England journal of medicine | 2022

von Sadoff, J. | Gray, G. | Vandebosch, A. | +127

3

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation : The Phase II SATURN study

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2017

von Forns, X. | Berenguer, M. | Herzer, K. | +16

4

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis : A phase 3 study (OPTIMIST-2)

enthalten in: Hepatology (Baltimore, Md.) | 2016

von Lawitz, E. | Matusow, G. | DeJesus, E. | +17

CommentIn: Hepatology. 2016 Aug;64(2):330-2. - PMID 26992027

5

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis : OPTIMIST-1, a phase 3, randomized study

enthalten in: Hepatology (Baltimore, Md.) | 2016

von Kwo, P. | Gitlin, N. | Nahass, R. | +15

CommentIn: Hepatology. 2016 Oct;64(4):1385-6. - PMID 26970320

6

Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea

enthalten in: Journal of gastroenterology and hepatology | 2016

von Wei, L. | Han, T. | Yang, D. | +17

7

Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

enthalten in: Clinical pharmacokinetics | 2016

von Ouwerkerk-Mahadevan, S. | Snoeys, J. | Peeters, M. | +2

8

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

enthalten in: Clinical pharmacokinetics | 2016

von Ouwerkerk-Mahadevan, S. | Snoeys, J. | Peeters, M. | +2

9

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)

enthalten in: Hepatology | 2016

von Lawitz, E. | Matusow, G. | DeJesus, E. | +17

10

Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study

enthalten in: Hepatology | 2016

von Kwo, P. | Gitlin, N. | Nahass, R. | +15

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]